Genesis Pharmaceuticals Ltd - matokeo ya utafutaji kwa

Israeli - Kiingereza - Ministry of Health

kaletra oral solution

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Marekani - Kiingereza - NLM (National Library of Medicine)

quviviq- daridorexant tablet, film coated

idorsia pharmaceuticals ltd - daridorexant (unii: lmq24g57e9) (daridorexant - unii:lmq24g57e9) - quviviq is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see clinical studies (14.1)] . quviviq is contraindicated: - in patients with narcolepsy. - in patients with a history of hypersensitivity to daridorexant or any components of quviviq. angioedema with pharyngeal involvement has been reported [see adverse reactions (6.2)] . pregnancy exposure registry there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to quviviq during pregnancy. pregnant women exposed to quviviq and healthcare providers are encouraged to call idorsia pharmaceuticals ltd at 1-833-400-9611. risk summary there are no available data on quviviq use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesi

Israeli - Kiingereza - Ministry of Health

ubrelvy 100 mg

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 100 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.

Israeli - Kiingereza - Ministry of Health

ubrelvy 50 mg

abbvie biopharmaceuticals ltd, israel - ubrogepant as trihydrate - tablets - ubrogepant as trihydrate 50 mg - ubrelvy is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.limitations of useubrelvy is not indicated for the preventive treatment of migraine.